<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04701619</url>
  </required_header>
  <id_info>
    <org_study_id>BMR_2020_31</org_study_id>
    <nct_id>NCT04701619</nct_id>
  </id_info>
  <brief_title>Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)</brief_title>
  <acronym>IMMUNOSTROKE</acronym>
  <official_title>Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles&#xD;
      during the course of AIC management by reperfusion treatment and to monitor changes in these&#xD;
      different parameters over time. Post-hoc analyses will make it possible to correlate the&#xD;
      immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical&#xD;
      outcome in terms of post-AIC functional and cognitive disability.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients undergoing a reperfusion procedure as part of an ischemia stroke will be able to participate in the study.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immuno-inflammatory profile description in patients with ischemic stroke and eligible for reperfusion treatment</measure>
    <time_frame>Up to year</time_frame>
    <description>Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA preconfigurated panels for inflammatory biomarkers.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Stroke</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Immuno-inflammatory profile description in patients with ischemic stroke</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immuno-inflammatory profile description in patients with ischemic stroke</intervention_name>
    <description>Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers</description>
    <arm_group_label>Immuno-inflammatory profile description in patients with ischemic stroke</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presenting an ISCHEMIC STROKE for which reperfusion treatment is indicated according&#xD;
             to European and North American recommendations (intraveinous thrombolysis or&#xD;
             mechanical thrombectomy or a combination of both)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to performing a cerebral MRI (claustrophobia, pacemaker or other&#xD;
             implantable device contraindicating the performance of MRI)&#xD;
&#xD;
          -  Intracranial haemorrhage associated with AIC on initial imaging&#xD;
&#xD;
          -  Immunosuppressive treatment or corticosteroid therapy on admission of the patient&#xD;
&#xD;
          -  Pre-existing neurological disability limiting the neurological assessment to 3 months&#xD;
             (mRS&gt;2 on admission)&#xD;
&#xD;
          -  Dementia known and diagnosed pre-existing at ischemic stroke&#xD;
&#xD;
          -  Absolute or relative contraindication to gadolinium injection (history of true&#xD;
             allergic reaction or intolerance to gadobutrol, renal failure with creatinine&#xD;
             clearance &lt;15mL/min, pregnant or breastfeeding woman).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin Maier</last_name>
    <phone>0148036556</phone>
    <email>nmaier@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Am√©lie Yavchitz</last_name>
    <phone>0148036556</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

